7pm4

Publication Abstract from PubMed

Enzymatic hydrolysis of alpha-L-fucose from fucosylated glycoconjugates is consequential in bacterial infections and the neurodegenerative lysosomal storage disorder fucosidosis. Understanding human alpha-L-fucosidase catalysis, in an effort toward drug design, has been hindered by the absence of three-dimensional structural data for any animal fucosidase. Here, we have used cryoelectron microscopy (cryo-EM) to determine the structure of human lysosomal alpha-L-fucosidase (FucA1) in both an unliganded state and in complex with the inhibitor deoxyfuconojirimycin. These structures, determined at 2.49 A resolution, reveal the homotetrameric structure of FucA1, the architecture of the catalytic center, and the location of both natural population variations and disease-causing mutations. Furthermore, this work has conclusively identified the hitherto contentious identity of the catalytic acid/base as aspartate-276, representing a shift from both the canonical glutamate acid/base residue and a previously proposed glutamate residue. These findings have furthered our understanding of how FucA1 functions in both health and disease.

Cryo-EM structures of human fucosidase FucA1 reveal insight into substrate recognition and catalysis.,Armstrong Z, Meek RW, Wu L, Blaza JN, Davies GJ Structure. 2022 Jul 19. pii: S0969-2126(22)00270-2. doi:, 10.1016/j.str.2022.07.001. PMID:35907402^[2]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.